Skip to Main Content

Paper Details

A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk
4
2021
Author NameAffiliation
David A RizzieriDuke Cancer Institute, Duke University
  • 1 - 1

Datasets

Release 1.2